Rahul Nachnani

C‐Reactive Protein: Marker of risk for post‐traumatic stress disorder and its potential for a mechanistic role in trauma response and recovery

S. Powell, V. Risbrough, S. Friend, 2020, The European journal of neuroscience.

The Pharmacological Case for Cannabigerol

K. Vrana, W. Raup-Konsavage, Rahul Nachnani, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Minireview The Pharmacological Case for Cannabigerol

K. Vrana, W. Raup-Konsavage, Rahul Nachnani, 2021 .

THE PHARMACOLOGICAL CASE FOR CANNABIGEROL (CBG)

K. Vrana, W. Raup-Konsavage, Rahul Nachnani, 2020 .

Bi-allelic loss of human CTNNA2, encoding αN-catenin, leads to ARP2/3 over-activity and disordered cortical neuronal migration

Kiely N. James, Martin W. Breuss, I. Miller, 2018, Nature Genetics.

The Rise and Risk of Delta-8 THC (Delta-8-Tetrahydrocannabinol)

K. Vrana, W. Raup-Konsavage, Rahul Nachnani, 2022, Current Addiction Reports.

Low-Dose and Standard Overnight and Low Dose-Two Day Dexamethasone Suppression Tests in Patients with Mild and/or Episodic Hypercortisolism

I. McCutcheon, T. Friedman, Martin L. Lee, 2018, Hormone and Metabolic Research.

Biallelic loss of human CTNNA2, encoding αN-catenin, leads to ARP2/3 complex overactivity and disordered cortical neuronal migration

Kiely N. James, Martin W. Breuss, A. Caglayan, 2018, Nature Genetics.

Chronic Cannabigerol as an Effective Therapeutic for Cisplatin-Induced Neuropathic Pain

W. Raup-Konsavage, N. Graziane, Rahul Nachnani, 2023, Pharmaceuticals.

High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model

W. Raup-Konsavage, Rahul Nachnani, Diana E. Sepulveda, 2024, The Journal of pharmacology and experimental therapeutics.